![](https://news.europawire.eu/wp-content/uploads/2013/10/AstraZeneca-144x150.jpg)
London, UK, 03-6-2014 — /EuropaWire/ — AstraZeneca today announced that the US Food and Drug Administration (FDA) has designated its novel investigational drug AZD0914 as a Qualified Infectious Disease Product (QIDP) and awarded its development programme Fast Track status for the treatment … Read the full press release